Published on
Results from multicenter study are first to show improved production of coagulation factor VIII over prolonged period, leading to reduction or complete elimination of bleeding events.
Published on
CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.
Published on
CHOP researchers have identified BAFF as a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.
Published on
CHOP researchers identified an in vivo role for activated protein C (APC), which could potentially be exploited for future hemophilia A treatments.
Published on
CHOP volunteers make camp a reality for many kids with special medical needs. They not only keep them healthy, but they also take part of the activities and enjoy seeing kids being kids.
Published on
A laboratory study may set the stage for a new preventive treatment for hemophilia patients who now develop antibodies to the standard treatment and then require a bypass therapy.
Published on
CHOP breakthrough helps scientists edge closer to defeating a longtime enemy of human health: hemophilia, the inability to form blood clots.
Published on
A team of gene therapy researchers has reported on a highly active gene variant that achieved sustained factor levels in 10 adults, with no adverse effects.
Published on
Three CHOP researchers recently won grants for their work on hemophilia from the Bayer Hemophilia Awards Program.
Published on
Von Willebrand disease (VWD) is a bleeding disorder caused by having too little von Willebrand factor (VWF) protein or VWF that doesn’t work well.